A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/1997
11/05/1997	EP0804561A1 Regulated transcription of targeted genes and other biological events
11/05/1997	EP0804552A1 Redirection of cellular immunity by receptor chimeras
11/05/1997	EP0804501A1 Stabiliser mixture made from chromane derivatives and inert organic solvents, and microcapsules containing the said stabiliser mixture
11/05/1997	EP0804459A1 Therapeutic compound - fatty acid conjugates
11/05/1997	EP0804456A1 Peptide nucleic acid conjugates
11/05/1997	EP0804283A1 Aqueous solvent encapsulation method, apparatus and microcapsules
11/05/1997	EP0804248A2 Chemically modified interferon
11/05/1997	EP0804247A1 Selenium conjugates for the preparation of free radical pharmaceuticals
11/05/1997	EP0804246A1 Drug delivery agents incorporating mitomycin
11/05/1997	EP0804245A1 Collagen preparation for the controlled release of active substances
11/05/1997	EP0804244A1 Compositions including heme-containing proteins and methods relating thereto
11/05/1997	EP0804243A2 Pharmaceutical products containing thermally-inhibited starches
11/05/1997	EP0804242A1 The use of dimeticone as a transport and carrier system and/or drug delivery system
11/05/1997	EP0804241A1 Utilization of ethoxylated fatty acid esters as self-emulsifiable compounds
11/05/1997	EP0804225A1 Pharmaceutical compositions comprising a superoxide dismutase
11/05/1997	EP0804223A1 Hgh containing pharmaceutical compositions
11/05/1997	EP0804208A1 Effervescent composition containing iodinated polyvinylpyrrolidone, and use thereof for disinfection
11/05/1997	EP0804194A1 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
11/05/1997	EP0804191A1 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
11/05/1997	EP0804173A1 Controlled release biodegradable microspheres and method of preparation
11/05/1997	EP0804172A1 Controlled release potassium dosage form
11/05/1997	EP0804170A2 Method for making freeze dried drug dosage forms
11/05/1997	EP0804169A1 Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
11/05/1997	EP0804168A1 Taste masked composition containing a drug/polymer complex
11/05/1997	EP0804167A1 Spheronization process using charged resins
11/05/1997	EP0804166A1 Controlled release formulation (albuterol)
11/05/1997	EP0804165A1 Solid medicament form with active agent distributed in polymer material
11/05/1997	EP0804163A1 Improved method for stabilization of biological substances during drying and subsequent storage and compositions thereof
11/05/1997	EP0804162A1 Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanocrystal formulation
11/05/1997	EP0804159A1 Sphingosomes for enhanced drug delivery
11/05/1997	EP0804157A1 Aerosol drug formulations containing vitamin e
11/05/1997	EP0804155A1 Composition and method for enhancing transdermal electrotransport agent delivery
11/05/1997	EP0804153A1 Compositions comprising a tissue glue and therapeutic agents
11/05/1997	EP0804146A1 Polyglycerine polyricinoleates
11/05/1997	EP0804144A1 Solid protector against uv, process for its preparation and use thereof
11/05/1997	EP0804088A1 Stabilized composition comprising colistin sulfate
11/05/1997	CN1164189A Parenteral pharmaceutical compositions containing GF 120918A
11/05/1997	CN1164185A Lyophilized preparation providing reversibly thermogelling water-base medicinal composition
11/05/1997	CN1163936A Recombination eukaryotic vector containing sensitinogen gene and application thereof
11/05/1997	CN1163900A Preparation of water-soluble copolymers of at least one water-soluble N-vinyllactam and at least one hydrophobic comonomer
11/05/1997	CN1163896A Transfection competent molecules
11/05/1997	CN1163895A Novel prodrugs for therapy of tumors and inflammatory disorders
11/04/1997	US5684221 Mammalian model of a malignant disorder
11/04/1997	US5684178 Compounds for cosmetics or foods
11/04/1997	US5684169 Dissolving taxol in cyclodextrin with stirring and shaking
11/04/1997	US5684145 Carrier system against GNRH
11/04/1997	US5684136 Fusion proteins and immunoglobulins
11/04/1997	US5684044 Mixed with amphoteric or pseudoamphoteric agent
11/04/1997	US5684040 Compositions in the form of solid solutions
11/04/1997	US5684009 Parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamides
11/04/1997	US5683993 Compositions and methods for stabilizing polymers
11/04/1997	US5683740 Covering of protein and phospholipids around cores of lipids for cosmmetics
11/04/1997	US5683723 Nanoparticles based on a polyoxyethelene and polyactic acid block copolymer
11/04/1997	US5683716 Improved oral absorption of poorly soluble drugs
11/04/1997	US5683715 Taxane-containing phosphatidylcholine liposomes
11/04/1997	US5683713 Transdermal penetration for antioxidants of mercaptoacids, mercaptoesters and amides
11/04/1997	US5683711 Transdermal drug delivery of estrogen hormones
11/04/1997	US5683710 Percutaneous absorption preparation
11/04/1997	US5683709 Poly(benzalkonium salt) as an anti-microbial agent for aqueous drug compositions
11/04/1997	US5683694 Method for the treatment of tumors with conjugated antibody A5B7 and a prodrug
11/04/1997	US5683684 Use of sphingolipids in the preparation of a cosmetic or dermopharmaceutical composition protecting the skin and hair against the harmful effects of atmospheric pollution
10/1997
10/30/1997	WO1997040177A1 Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
10/30/1997	WO1997040161A1 Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
10/30/1997	WO1997040070A1 Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (vip)
10/30/1997	WO1997039770A1 New pharmaceutical formulation of a thrombin inhibitor for parenteral use
10/30/1997	WO1997039768A1 A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent
10/30/1997	WO1997039763A1 Compositions comprising antifungal agent and acetate buffer
10/30/1997	WO1997039762A1 Stabilized antihepatitis-b vaccine tablets
10/30/1997	WO1997039758A1 Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
10/30/1997	WO1997039755A1 Oral pharmaceutical preparation containing ibandronat
10/30/1997	WO1997039747A1 Taste masked paracetamol compositions
10/30/1997	WO1997039746A1 Method of and composition for treating disorders of the skin using vitamin k
10/30/1997	WO1997039745A1 Use of inhaled retinoids in the prevention of cancer
10/30/1997	WO1997039744A1 Immediate release ph-independent solid dosage form of cisapride
10/30/1997	WO1997039743A1 Transdermal contraceptive delivery system
10/30/1997	WO1997039742A1 Transdermally administered dextromethorphan as antitussive agent
10/30/1997	WO1997039739A2 Polyol composition
10/30/1997	WO1997039738A2 Sustained release ionic conjugate
10/30/1997	WO1997039731A1 Use of lactic acid esters
10/30/1997	WO1997039632A1 Natural antioxidant composition
10/30/1997	WO1997029779A3 EGF-Genistein conjugates for the treatment of cancer
10/30/1997	WO1997025070A3 Lipophilic peptides for macromolecule delivery
10/30/1997	DE19616585A1 Complex of cyclodextrin or derivative and 3-deoxy-D-glycero-pentulose
10/30/1997	CA2285184A1 Stabilized antihepatitis-b vaccine tablets
10/30/1997	CA2252826A1 Sustained release ionic conjugate
10/30/1997	CA2252458A1 Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (vip)
10/30/1997	CA2252439A1 Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
10/29/1997	EP0803255A1 Medicinal composition
10/29/1997	EP0803254A1 Alcoholic solutions containing acetylsalicylic acid for percutaneous administration, their use in antithrombotic therapy and medicaments
10/29/1997	EP0803253A1 Matrix-type oral sustained-release tablets containing tianeptine sodium salt
10/29/1997	EP0803250A1 Controlled release of steroids from sugar coatings
10/29/1997	EP0803249A2 Cholesterol lowering drink mix compositions
10/29/1997	EP0802985A1 Cell cycle regulated repressor and dna element
10/29/1997	EP0802980A1 Nucleic acid immunization using a virus-based infection/transfection system
10/29/1997	EP0802924A1 Antibodies against t-cells as therapeutics
10/29/1997	EP0802799A1 BIOTHERAPY OF CANCER BY TARGETING TP-3/p80
10/29/1997	EP0802798A1 Method and compositions for increasing the serum half-life of pharmacologically active agents
10/29/1997	EP0802792A1 Therapeutic treatment for inhibiting vascular restenosis
10/29/1997	EP0802790A1 Transdermal therapeutic system for dispensing (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazole or one of its pharmaceutically acceptable salts
10/29/1997	EP0802788A1 Novel therapeutic delivery systems

1 ... 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 ... 1712